A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ganciclovir (Primary)
- Indications CNS infections; Cytomegalovirus infections
- Focus Therapeutic Use
- 27 Aug 2010 Biomarkers information updated
- 22 Nov 2005 New trial record.